Healthline: At-Home COVID-19 test gets FDA warning: What to know
UC infectious disease expert says the biggest risk is a false negative test
The Food and Drug Administration (FDA) announced recently that people should stop using the E25Bio rapid COVID-19 test. The agency warned that the test contains false labeling and instructions. The manufacturer says the E25Bio test uses a “novel technology” that is more accurate than a PCR test “without the need for equipment and at a fraction of the cost and time.”
However, according to the FDA, this test hasn’t been “authorized, cleared, or approved” by the FDA for distribution or use in the United States and may include false labeling claiming that the test is authorized by the FDA.
In a story published by Healthline, Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine was the only expert source cited, saying that in an emergency, manufacturers might rush a product to market and don’t have to deal with full FDA approval.
Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine/Photo/Colleen Kelley/UC Creative + Brand
“Usually, this is uncommon as most retailers typically sell products that are FDA approved,” he added.
Fichtenbaum explained that the main danger is a false negative test.
“If someone really has COVID, and then assumes they don’t based upon a faulty or inaccurate test, they could infect others and become sicker themselves and not seek medical attention as quickly as they should,” he said.
According to Fichtenbaum, false positives can occur, and this could cause unnecessary concern and worry.
“Also, if people isolate, they might lose income or their job,” he continued.
The dangers associated with taking your own samples aren’t the biggest issue, Fichtenbaum said. The main concern is “inadequate” sample collection.
“People may not swab correctly or collect the right amount of saliva,” he said. “This can lower the effectiveness of the test and provide mostly false-negative results.”
Lead image/Boston 25 News
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's medical, graduate and undergraduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
How the University of Cincinnati co-op program is shaping the future of work at SXSW
March 17, 2026
The University of Cincinnati served as a 2026 Workplace Track sponsor at the annual South by Southwest (SXSW) Innovation Conference March 12-18 in Austin, Texas, showcasing how co-op is redesigning the future of work.
Recent advances may speed time to endometriosis diagnosis
March 16, 2026
The average time to clinical diagnosis of endometriosis is nine years. Definitive diagnosis of the disease is difficult, and until recently, has relied on laparoscopic surgery. Now, as Medscape recently reported, novel clinical recommendations, advanced diagnostic tools and research into inflammation and immune responses, are bringing promise that women with endometriosis will find relief sooner and without surgery, according to experts, including Katie Burns, PhD, University of Cincinnati College of Medicine associate professor.
Position-specific helmets may not improve protection
March 16, 2026
Local 12 highlighted a new study by biomedical engineering researchers that looked at how well new football helmets protected players from impacts that can cause concussions.